Enfusion Q4 2023 Adj EPS $0.04 Misses $0.05 Estimate, Sales $46.486M Beat $45.275M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enfusion (NYSE:ENFN) reported Q4 2023 adjusted EPS of $0.04, missing the consensus estimate of $0.05 by 20%. However, their sales of $46.486M exceeded the estimate of $45.275M by 2.67%, marking a 14.73% increase from the previous year.
March 12, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Enfusion reported a Q4 2023 adjusted EPS of $0.04, missing estimates by 20%, but sales of $46.486M exceeded expectations, showing a 14.73% YOY growth.
The miss in EPS might concern investors, potentially putting downward pressure on ENFN's stock in the short term. However, the beat on sales and significant year-over-year growth could offset concerns, suggesting a neutral short-term impact. The mixed results present both positive and negative signals to the market.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100